TYRP1 and neoplasm: Despite the absence of radiographic tumor shrinkage, biological activity was evident; Smith reported dose-dependent Tyrosinase Related Protein 1 (TYRP1)-specific T-cell expansion and epitope spreading, with two patients subsequently deriving durable benefit from immune-checkpoint blockade.